招银国际发表研究报告指，和黄医药上半年肿瘤及免疫产品收入按年跌15%至1.44亿美元，仅达该行全年预测的36%，主要因核心产品内地销售收入下跌。管理层对下半年仍持乐观态度，基于fruquintinib用于子宫内膜癌(EMC)适应症上市、savolitinib MET+ EGFRm非小细胞肺癌(NSCLC)二线疗法获批，以及销售团队重组完成；管理层又指销售已于首季触底，次季起恢复增长。 公司将全年肿瘤及免疫产品收入目标由3.5亿至4.5亿美元下调至2.7亿至3.5亿美元，而该行对指引持保守看法，因考虑到fruquintinib海外销售按季持平，以及国内市场竞争持续。该行维持对其“买入”评级，基于上半年业绩一般以及指引下调，目标价由34.03港元降至31.39港元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.